Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation

Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation

Background: Several therapies have recently been approved for use in the NHS for pretreated advanced or metastatic renal cell carcinoma (amRCC), but there is a lack of comparative evidence to guide decisions between them. Objective: To evaluate the clinical effectiveness and cost-effectiveness of ax...

Full description

Bibliographic Details
Main Authors: Steve J Edwards, Victoria Wakefield, Peter Cain, Charlotta Karner, Kayleigh Kew, Mariana Bacelar, Natalie Masento, Fatima Salih
Format: Article
Language:English
Published: NIHR Journals Library 2018-01-01
Series:Health Technology Assessment
Subjects:
carcinoma
renal cell
sunitinib
cabozantinib
axitinib
disease-free survival
nivolumab
everolimus
odds ratio
cost-benefit analysis
vascular endothelial growth factor a
medline
quality-adjusted life years
quality of life
state medicine
pyrroles
indoles
anilides
pyridines
imidazoles
indazoles
antibodies
monoclonal
disease progression
Online Access:https://doi.org/10.3310/hta22060

Internet

https://doi.org/10.3310/hta22060

Similar Items